- Home
- OTLK vs RFL Comparison
OTLK vs RFL Comparison
Compare OTLK & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- RFL
- Stock Information
- Founded
- OTLK 2010
- RFL 2017
- Country
- OTLK United States
- RFL United States
- Employees
- OTLK N/A
- RFL N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- RFL Real Estate
- Sector
- OTLK Health Care
- RFL Finance
- Exchange
- OTLK Nasdaq
- RFL Nasdaq
- Market Cap
- OTLK 48.3M
- RFL 48.4M
- IPO Year
- OTLK 2016
- RFL N/A
- Fundamental
- Price
- OTLK $1.57
- RFL $1.93
- Analyst Decision
- OTLK Strong Buy
- RFL
- Analyst Count
- OTLK 5
- RFL 0
- Target Price
- OTLK $9.60
- RFL N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- RFL 462.2K
- Earning Date
- OTLK 08-13-2025
- RFL 06-11-2025
- Dividend Yield
- OTLK N/A
- RFL N/A
- EPS Growth
- OTLK N/A
- RFL N/A
- EPS
- OTLK 0.83
- RFL N/A
- Revenue
- OTLK N/A
- RFL $732,000.00
- Revenue This Year
- OTLK N/A
- RFL N/A
- Revenue Next Year
- OTLK $379.84
- RFL N/A
- P/E Ratio
- OTLK $1.91
- RFL N/A
- Revenue Growth
- OTLK N/A
- RFL 35.56
- 52 Week Low
- OTLK $0.87
- RFL $1.27
- 52 Week High
- OTLK $9.25
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- RFL 51.93
- Support Level
- OTLK $1.65
- RFL $1.56
- Resistance Level
- OTLK $2.04
- RFL $1.84
- Average True Range (ATR)
- OTLK 0.12
- RFL 0.20
- MACD
- OTLK -0.03
- RFL -0.03
- Stochastic Oscillator
- OTLK 2.13
- RFL 28.68
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.